CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia.Xin Jin,Rui Sun,Zhu Li,Xianwu Wang,Xia Xiong,Wenyi Lu,Hairong Lyu,Xia Xiao,Yunpeng Tian,Hongkai Zhang,Zhihong Fang,Luqiao Wang,Mingfeng ZhaoHaematologica(2024)引用 0|浏览21暂无评分摘要Not available.更多查看译文AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要